US Patent Issued to Geneheal Biotechnology on July 28 for "Application of compounds in the preparation of reagents for down-regulation of RUNX2" (Chinese Inventors)

ALEXANDRIA, Va., July 28 -- United States Patent no. 12,693,289, issued on July 28, was assigned to Geneheal Biotechnology Co. Ltd. (Guangzhou, China).

"Application of compounds in the preparation of reagents for down-regulation of RUNX2" was invented by Wuguang Pan (Guangzhou, China) and Wei Zhu (Guangzhou, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention discloses application of compounds in the preparation of reagents for down-regulation of Runx2. The inventors have confirmed through computational studies and disease models that Fostamatinib, Regorafenib and melatonin can significantly down-regulate the expression of Runx2, and have a significant targeted therapeutic effect on ca...